Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 154 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Liver resection Clear all

Conditions: Carcinoma, Hepatocellular
Interventions: Nexavar (Sorafenib, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more

Conditions: Liver Tumor
Interventions: RFA controlled using echo decorrelation imaging, RFA controlled using standard manufacturer-specified algorithms; Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Colorectal Cancer Metastatic
Interventions: Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373; Combination Product
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Lake Success, New York • New Hyde Park, New York

Conditions: Liver Transplant
Interventions: arTreg, leukapheresis, cyclophosphamide, mesna, everolimus; Biological · Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease
Interventions: Surgery; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Liver Cancer, Metastatic Cancer
Interventions: Yttrium Y 90 glass microspheres; Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anastomotic Stenosis, Biliary Stricture
Interventions: Protocol for increasing number of stents across the anastomosis; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hepatic Cancer
Interventions: Galactose, Standard Treatment; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Liver and Intrahepatic Bile Duct Neoplasm
Interventions: Electronic Health Record Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Hepatocellular Carcinoma, Localized Resectable Adult Liver Carcinoma
Interventions: Computed Tomography, 18F-fluoromethylcholine, Positron Emission Tomography; Diagnostic Test · Drug
Lead sponsor: Queen's Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Floxuridine, Intrahepatic Infusion Procedure, Leronlimab, Magnetic Resonance Imaging, Surgical Procedure, Systemic Therapy; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Goodyear, Arizona • Duarte, California • Irvine, California

Conditions: Liver Cancer
Interventions: 18F-Fluorodeoxyglucose-PET (FDG-PET), 11Carbon-Acetate-PET; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Laparoscopic Hepatectomy, Laparoscopic Liver Thermal Ablation
Interventions: LapAR; Device
Lead sponsor: IGI Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatocellular Carcinoma
Interventions: Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: Leucovorin, Oxaliplatin, 5-FU, Irinotecan; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Disease, Pain
Interventions: paravertebral blocks; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Cisplatin, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Emory University; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: Atlanta, Georgia • Rochester, Minnesota • Portland, Oregon + 2 more

Conditions: Liver Cancer Adult, Liver Regeneration
Interventions: carbon monoxide measurement via smokerlyzer; Other
Lead sponsor: Englewood Hospital and Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Pancreatic Neoplasms, Neoplasm Metastasis, Liver Metastases
Interventions: Hepatic Resection or Ablation with Pancreaticoduodenectomy; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions: everolimus, placebo; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: LFSD; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 6 Years to 9 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Intrahepatic Cholangiocarcinoma (Icc)
Interventions: EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Liver Diseases, Surgery
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: dexamethasone, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

Liver Transplantation With Tregs at UCSF

Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

Evaluation of Sequential Stent Addition vs. Incremental Dilation & Stent Exchange for Management of Anastomotic Biliary Strictures After Liver Transplantation

Direct Peritoneal Resuscitation Plus Conventional Resuscitation

Effect of Materials for Subcuticular Suture (Quill vs. Monocryl) on Complications After Liver Resection

PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection

CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial

Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer

Assessment of Augmented Reality in Minimally Invasive Surgery

Trial Comparing PLA to HIGRT (PROVE-HCC)

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Comparison Between Epidural and Bilateral Paravertebral Blocks in Liver Resection

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy

Hepatic Resection for Metastatic Pancreatic Cancer

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Prevention of NAFLD in Hispanic Children

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

Longitudinal Outcomes in Hepatic Resection

Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer